Raisio (RAIKV) Q3 2026 earnings summary

Executive summary

• Q3 net sales rose 2.1% YoY to €57.8m; comparable EBIT declined 2.2% to €8.4m from €8.6m, with margin at 14.6% versus 15.3%.

• 9M net sales increased 1.3% to €171.3m; comparable EBIT fell 5.2% to €21.5m, reflecting ERP costs and weaker Heart Health performance.

Financial highlights

• Q3 comparable EBITDA was €10.7m, down 2.3% YoY; 9M comparable EBITDA was €28.4m, down 4.3%.

• 9M reported EBIT fell 20.1% to €17.6m, including a €4.3m Kauhava impairment; net income was €14.5m versus €18.4m.

• Q3 net income was €6.3m versus €7.2m; EPS and comparable EPS were €0.04 versus €0.05. 9M EPS was €0.09 versus €0.12; comparable EPS was €0.11 versus €0.12.

• 9M operating cash flow after financial items and taxes was €20.4m versus €23.7m; cash flow before working-capital changes was €27.8m versus €28.7m.

• Q3 comparable EBIT included €0.5m of ERP reorganisation costs and €0.2m of other ERP impact; 9M ERP impact was €1.8m.

Outlook and guidance

• Updated 6 November 2026: FY26 net sales are projected at the FY25 level; comparable EBIT is expected at the FY25 level or to decrease slightly.

• Earlier guidance projected increases in both net sales and comparable EBIT versus 2025; it was revised as growth remained below expectations.